Grifols (GRFS) Non-Current Deferred Tax Liability (2010 - 2025)
Grifols (GRFS) reported Non-Current Deferred Tax Liability of $1.0 billion for Q4 2025, down 7.32% on a YoY basis from $1.1 billion in Q4 2024, and down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024.
Grifols (GRFS) Non-Current Deferred Tax Liability (2010 - 2025) Analysis & Trends
Grifols has reported Non-Current Deferred Tax Liability for 16 years, with the latest figure at $1.0 billion in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (down 7.32% YoY), and the FY2025 full-year result was $1.0 billion, down 7.32% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $1.0 billion, down from $1.1 billion in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.1 billion in Q4 2024, with the low at $725.3 million in Q4 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $985.7 million across 5 years, with a median of $1.1 billion in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 45.57% — and 2025, when it decreased 7.32%.
- Grifols' Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then gained by 0.75% to $1.1 billion in 2023, then advanced by 1.67% to $1.1 billion in 2024, then declined by 7.32% to $1.0 billion in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $1.0 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Dec 31, 2017 | 457.92 Mn |
| Dec 31, 2017 | 457.92 Mn |